Key result
Individuals with severe preserved ratio impaired spirometry (PRISm) and metabolic syndrome had a markedly increased risk of all-cause mortality (HR 5.32).
Why the study?
Does metabolic syndrome increase the risk of cardiopulmonary morbidity and mortality in adults with impaired lung function?
Does metabolic syndrome increase the risk of cardiopulmonary morbidity and mortality in adults with impaired lung function?
Answers are grounded in this paper and cite their sources.
Metabolic syndrome significantly exacerbates the risk of cardiopulmonary morbidity and all-cause mortality in individuals with impaired lung function.
Impaired lung function, either with airflow limitation or with preserved ratio impaired spirometry (PRISm), is common globally and associated with increased cardiorespiratory morbidity, cause-specific mortality and overall mortality.1,2 In this context, understanding the impact of metabolic syndrome on cardiopulmonary outcomes is clinically important, given the growing global prevalence of metabolic syndrome, driven in part by the increasing obesity rates, and its associations with major adverse cardiovascular events and all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Sadeghimakki et al. (2023) conducted an editorial in Impaired lung function (PRISm or airflow limitation) (n=106,845). Metabolic syndrome vs. No metabolic syndrome was evaluated on All-cause mortality in individuals with severe PRISm and metabolic syndrome (HR 5.32, 95% CI 3.76-7.54). Individuals with severe preserved ratio impaired spirometry (PRISm) and metabolic syndrome had a markedly increased risk of all-cause mortality (HR 5.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: